Structures by: Pidcock E.
Total: 146
C15H14N4O,C7H6O2
C15H14N4O,C7H6O2
CrystEngComm (2020)
a=9.934(2)Å b=8.360(2)Å c=23.571(6)Å
α=90° β=92.977(8)° γ=90°
C15H14N4O,0.5(C7H6O3)
C15H14N4O,0.5(C7H6O3)
CrystEngComm (2020)
a=7.2706(14)Å b=9.5902(19)Å c=11.881(2)Å
α=96.11(3)° β=92.79(3)° γ=98.34(3)°
C15H14N4O,0.5(C7H6O4)
C15H14N4O,0.5(C7H6O4)
CrystEngComm (2020)
a=7.1010(3)Å b=9.4938(4)Å c=12.0005(5)Å
α=95.619(2)° β=92.881(2)° γ=99.035(2)°
Salicylaldoxime
C7H7N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=10.346(4)Å b=5.0294(17)Å c=13.478(5)Å
α=90° β=112.21(2)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=6.6132(3)Å b=13.1087(6)Å c=13.6382(6)Å
α=68.762(3)° β=76.739(3)° γ=79.733(3)°
3-Methylsalicylaldoxime
C8H9N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.249(4)Å b=3.9513(11)Å c=14.402(4)Å
α=90° β=90.324(4)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.1506(18)Å b=3.8859(6)Å c=14.3115(19)Å
α=90° β=91.548(10)° γ=90°
3-Methoxysalicylaldoxime
C8H9N1O3
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.9108(5)Å b=7.1936(3)Å c=15.6965(6)Å
α=90° β=90° γ=90°
Indomethacin Nicotinamide (1/1)
C19H16ClNO4,C6H6N2O
CrystEngComm (2013) 15, 20 4041
a=17.1980(8)Å b=5.0156(2)Å c=27.3815(15)Å
α=90° β=97.311(2)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
CrystEngComm (2008) 10, 2 239
a=13.1506(18)Å b=3.8859(6)Å c=14.3115(19)Å
α=90° β=91.548(10)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=13.249(4)Å b=3.9513(11)Å c=14.402(4)Å
α=90° β=90.324(4)° γ=90°
3-Methoxysalicylaldoxime
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=13.9108(5)Å b=7.1936(3)Å c=15.6965(6)Å
α=90° β=90° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.998(3)Å b=3.6988(5)Å c=13.9167(16)Å
α=90° β=90.99(2)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.941(4)Å b=3.6146(5)Å c=13.7188(17)Å
α=90° β=91.47(2)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.878(4)Å b=3.5363(5)Å c=13.5218(16)Å
α=90° β=91.88(2)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.766(7)Å b=3.4872(9)Å c=13.382(3)Å
α=90° β=92.27(4)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.750(4)Å b=3.4482(6)Å c=13.2910(18)Å
α=90° β=92.45(2)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=14.811(3)Å b=6.4564(7)Å c=19.759(4)Å
α=90° β=94.060(8)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=14.5745(13)Å b=6.3779(4)Å c=19.0922(18)Å
α=90° β=94.882(4)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=14.3941(14)Å b=6.3329(4)Å c=18.7250(19)Å
α=90° β=95.325(5)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=14.271(4)Å b=6.3030(9)Å c=18.459(5)Å
α=90° β=95.590(15)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=14.101(3)Å b=6.2699(6)Å c=18.158(3)Å
α=90° β=95.817(10)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
CrystEngComm (2008) 10, 2 239
a=12.748(2)Å b=3.5954(3)Å c=13.6496(15)Å
α=90° β=93.115(13)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
CrystEngComm (2008) 10, 2 239
a=12.652(4)Å b=3.5295(4)Å c=13.509(2)Å
α=90° β=93.64(2)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
CrystEngComm (2008) 10, 2 239
a=12.544(6)Å b=3.4424(8)Å c=13.365(5)Å
α=90° β=94.44(4)° γ=90°
C8H9N1O3
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=12.3113(5)Å b=6.9800(4)Å c=14.8947(5)Å
α=90° β=90° γ=90°
C8H9N1O3
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=12.5814(4)Å b=7.0265(4)Å c=15.0188(4)Å
α=90° β=90° γ=90°
C8H9N1O3
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=12.1340(13)Å b=6.9421(11)Å c=14.8065(13)Å
α=90° β=90° γ=90°
C8H9N1O3
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=12.0702(5)Å b=6.9200(5)Å c=14.7703(5)Å
α=90° β=90° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=6.6132(3)Å b=13.1087(6)Å c=13.6382(6)Å
α=68.762(3)° β=76.739(3)° γ=79.733(3)°
3-tButylsalicylaldoxime
C11H15N1O2
CrystEngComm (2008) 10, 2 239
a=6.5597(7)Å b=12.8532(9)Å c=13.479(2)Å
α=69.311(10)° β=76.054(10)° γ=79.035(6)°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.57203(67)Å b=9.30117(49)Å c=5.60429(45)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.48770(68)Å b=9.09431(54)Å c=5.57539(47)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.44354(73)Å b=8.96414(56)Å c=5.55463(50)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.39175(69)Å b=8.80598(51)Å c=5.52187(50)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.35471(71)Å b=8.70622(53)Å c=5.49678(53)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.32162(60)Å b=8.62427(43)Å c=5.47386(41)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=8.30986(53)Å b=8.59508(39)Å c=5.46585(36)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=6.87000(33)Å b=9.63731(56)Å c=5.60664(30)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=6.81067(43)Å b=9.62266(69)Å c=5.59344(31)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=6.76267(42)Å b=9.60731(70)Å c=5.58248(37)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=6.68687(32)Å b=9.58023(58)Å c=5.56241(31)Å
α=90° β=90° γ=90°
L-serine-d7
C3D7NO3
CrystEngComm (2008) 10, 9 1154
a=6.54874(33)Å b=9.53864(54)Å c=5.60779(32)Å
α=90° β=90° γ=90°
Serine Monohydrate
C3H9N1O4
CrystEngComm (2008) 10, 12 1758
a=9.3344(6)Å b=11.822(3)Å c=4.7387(3)Å
α=90° β=90° γ=90°
Serine Monohydrate
C3H9N1O4
CrystEngComm (2008) 10, 12 1758
a=9.3563(6)Å b=11.443(2)Å c=4.6166(3)Å
α=90° β=90° γ=90°
Serine Monohydrate
C3H9N1O4
CrystEngComm (2008) 10, 12 1758
a=9.3706(6)Å b=11.204(2)Å c=4.5341(3)Å
α=90° β=90° γ=90°
Serine Monohydrate
C3H9N1O4
CrystEngComm (2008) 10, 12 1758
a=9.3728(5)Å b=11.0359(17)Å c=4.4782(3)Å
α=90° β=90° γ=90°
Serine Monohydrate
C3H9N1O4
CrystEngComm (2008) 10, 12 1758
a=9.8778(13)Å b=10.155(4)Å c=4.4175(7)Å
α=90° β=90° γ=90°
Serine hydrate
C3D7NO3,D2O1
CrystEngComm (2008) 10, 12 1758
a=9.3701(14)Å b=11.1831(10)Å c=4.52938(59)Å
α=90° β=90° γ=90°
Serine hydrate
C3D7NO3,D2O1
CrystEngComm (2008) 10, 12 1758
a=9.8641(14)Å b=10.09910(93)Å c=4.39860(65)Å
α=90° β=90° γ=90°
Pyrimethamine+carbamazepine+methanol
C15H12N2O,C12H13ClN4,2(CH4O)
CrystEngComm (2013) 15, 15 2916
a=7.96900(10)Å b=10.11220(10)Å c=17.9406(3)Å
α=92.9360(10)° β=94.1630(10)° γ=106.0620(10)°
Pyrimethamine+theophylline
C12H13ClN4,C7H8N4O2
CrystEngComm (2013) 15, 15 2916
a=7.9789(4)Å b=10.3092(5)Å c=13.6586(7)Å
α=68.186(3)° β=87.884(2)° γ=75.726(3)°
Pyrimethaminium+aspirinate+acetonitrile
C12H14ClN41,C9H7O41,C2H3N
CrystEngComm (2013) 15, 15 2916
a=10.0012(3)Å b=11.5494(4)Å c=11.7171(4)Å
α=107.432(2)° β=106.355(2)° γ=99.557(2)°
Pyrimethaminium+alpha-ketoglutarate
C12H14ClN41,C5H5O51
CrystEngComm (2013) 15, 15 2916
a=7.8393(2)Å b=11.0472(3)Å c=12.1060(4)Å
α=82.881(2)° β=71.670(2)° γ=69.719(2)°
Pyrimethaminium+p-coumarate+water
C12H14ClN41,C9H7O31,H2O
CrystEngComm (2013) 15, 15 2916
a=7.60860(10)Å b=9.9450(2)Å c=14.6138(3)Å
α=80.9630(10)° β=87.2240(10)° γ=72.8160(10)°
3-Methylsalicylaldoxime
C8H9N1O2
CrystEngComm (2008) 10, 2 239
a=12.831(3)Å b=3.5096(4)Å c=13.4462(13)Å
α=90° β=92.10(2)° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
CrystEngComm (2008) 10, 2 239
a=12.843(3)Å b=3.6613(3)Å c=13.7921(16)Å
α=90° β=92.603(13)° γ=90°
C8H9N1O3
C8H9N1O3
CrystEngComm (2008) 10, 2 239
a=13.0765(5)Å b=7.0982(4)Å c=15.2455(5)Å
α=90° β=90° γ=90°
Salicylaldoxime
C7H7N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=10.346(4)Å b=5.0294(17)Å c=13.478(5)Å
α=90° β=112.21(2)° γ=90°
3-Methylsalicylaldoxime
C8H9N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.249(4)Å b=3.9513(11)Å c=14.402(4)Å
α=90° β=90.324(4)° γ=90°
3-tButylsalicylaldoxime
C11H15N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=6.6132(3)Å b=13.1087(6)Å c=13.6382(6)Å
α=68.762(3)° β=76.739(3)° γ=79.733(3)°
3-Methoxysalicylaldoxime
C8H9N1O3
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.9108(5)Å b=7.1936(3)Å c=15.6965(6)Å
α=90° β=90° γ=90°
3-chlorosalicylaldoxime
C7H6Cl1N1O2
Chemical Communications (Cambridge, United Kingdom) (2007) 46 4940-4942
a=13.1506(18)Å b=3.8859(6)Å c=14.3115(19)Å
α=90° β=91.548(10)° γ=90°
Salicylamide
C7H7N1O2
CrystEngComm (2010) 12, 4 1065
a=12.8887(8)Å b=4.9700(3)Å c=20.9607(19)Å
α=90° β=91.546(4)° γ=90°
Salicylamide
C7H7N1O2
CrystEngComm (2010) 12, 4 1065
a=12.7925(11)Å b=4.9356(5)Å c=20.415(5)Å
α=90° β=92.266(14)° γ=90°
Salicylamide
C7H7N1O2
CrystEngComm (2010) 12, 4 1065
a=12.5438(6)Å b=4.8464(3)Å c=19.203(3)Å
α=90° β=93.648(7)° γ=90°
Salicylamide
C7H7N1O2
CrystEngComm (2010) 12, 4 1065
a=12.3706(7)Å b=4.7918(3)Å c=18.398(3)Å
α=90° β=94.078(8)° γ=90°
Salicylamide
C7H7N1O2
CrystEngComm (2010) 12, 4 1065
a=3.8938(4)Å b=5.5612(6)Å c=28.566(8)Å
α=90° β=90° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.6168(2)Å b=15.2552(5)Å c=52.3376(16)Å
α=90° β=89.976(2)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.3592(7)Å b=14.601(2)Å c=51.188(9)Å
α=90° β=89.989(10)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.2634(3)Å b=14.4120(11)Å c=50.836(4)Å
α=90° β=89.966(5)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.6837(2)Å b=15.5843(6)Å c=52.1546(16)Å
α=90° β=89.933(2)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.1346(6)Å b=14.165(2)Å c=50.433(8)Å
α=90° β=89.880(9)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.701(2)Å b=12.569(6)Å c=24.786(13)Å
α=90° β=90° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.0316(6)Å b=14.0254(19)Å c=50.157(8)Å
α=90° β=89.796(9)° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.6475(7)Å b=12.451(3)Å c=24.651(2)Å
α=90° β=90° γ=90°
Methyl 2-(9H-carbazol-9-yl)benzoate
C20H15N1O2
CrystEngComm (2010) 12, 9 2520
a=7.6285(8)Å b=12.299(3)Å c=24.555(3)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.4715(4)Å b=11.4963(5)Å c=13.0802(6)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.431(3)Å b=11.438(7)Å c=13.018(3)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.0252(5)Å b=11.0298(14)Å c=12.3350(6)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.1517(6)Å b=11.1659(16)Å c=12.5744(7)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.9440(5)Å b=10.9336(14)Å c=12.1698(6)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.8854(5)Å b=10.8632(14)Å c=12.0516(6)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.8458(5)Å b=10.8143(14)Å c=11.9708(6)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.8188(6)Å b=10.7838(17)Å c=11.9105(8)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.7881(13)Å b=10.735(2)Å c=11.859(2)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.778(2)Å b=10.656(4)Å c=11.884(3)Å
α=90° β=90° γ=90°
Betaine monohydrate
C5H13N1O3
Acta Crystallographica Section B (2009) 65, 6 731-748
a=8.7873(10)Å b=10.710(2)Å c=11.8632(12)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.9233(2)Å b=19.0222(5)Å c=5.3030(2)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.8922(2)Å b=19.0021(19)Å c=5.2919(2)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.7622(2)Å b=18.7945(19)Å c=5.2343(2)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.5490(3)Å b=18.259(3)Å c=5.1169(3)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.4955(4)Å b=18.000(4)Å c=5.0930(4)Å
α=90° β=90° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.4885(14)Å b=17.834(7)Å c=5.0983(13)Å
α=90° β=90° γ=90°
S-4-Sulfo-L-Phenylalanine monohydrate
C9H13N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.5299(5)Å b=7.6432(6)Å c=11.6081(9)Å
α=90° β=93.590(5)° γ=90°
L-Cysteic acid monohydrate
C3H9N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.6284(3)Å b=18.508(3)Å c=5.1615(3)Å
α=90° β=90° γ=90°
S-4-Sulfo-L-Phenylalanine monohydrate
C9H13N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=6.3782(3)Å b=7.4754(3)Å c=11.4450(13)Å
α=90° β=92.591(7)° γ=90°
S-4-Sulfo-L-Phenylalanine monohydrate
C9H13N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=10.2176(8)Å b=8.2463(5)Å c=12.6853(17)Å
α=90° β=114.238(9)° γ=90°
S-4-Sulfo-L-Phenylalanine monohydrate
C9H13N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.9602(9)Å b=8.1894(6)Å c=12.475(2)Å
α=90° β=113.060(11)° γ=90°
S-4-Sulfo-L-Phenylalanine monohydrate
C9H13N1O6S1
Acta Crystallographica Section B (2009) 65, 6 731-748
a=9.7934(8)Å b=8.1603(5)Å c=12.3534(17)Å
α=90° β=112.384(9)° γ=90°